References
- Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol 2006; 45:897–908.
- Augustine M, Sharma P, Stephen J, Jayaseelan E. Fixed drug eruption and generalised erythema following etoricoxib. Indian J Dermatol Venereol Leprol 2006; 72:307–309.
- Atzori L, Pinna AL, Pau M, Aste N, Zucca M, Ferreli C. Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center. J Cutan Med Surg 2006; 10:31–35.
- Thirion L, Nikkels AF, Piérard GE. Etoricoxib-induced erythema-multiforme-like eruption. Dermatology 2008; 216:227–228.
- Mäkelä L, Lammintausta K. Etoricoxib-induced acute generalized exanthematous pustulosis. Acta Derm Venereol 2008; 88:200–201.
- Duarte AF, Correia O, Azevedo R, do Carmo Palmares M, Delgado L. Bullous fixed drug eruption to etoricoxib—further evidence of intraepidermal CD8+ T cell involvement. Eur J Dermatol 2010; 20:236–238.
- Bandyopadhyay D.Celecoxib-induced fixed drug eruption. Clin Exp Dermatol 2003; 28:452.
- Bellini V, Stingeni L, Lisi P. Multifocal fixed drug eruption due to celecoxib. Dermatitis 2009; 20:174–176.
- Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9:316–321.
- Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321–328.
- Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005; 95:438–442.
- Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005; 94: 34–38.